The association of germline BRCA1 and BRCA2 PGVs with high-risk breast cancer predisposition has been well recognized and clinical diagnostic testing of these genes has been offered for the past 23 years in Manchester. This evidence concerns the gene BRCA1 and breast carcinoma.